- Home
- ACIU vs DSM Comparison
ACIU vs DSM Comparison
Compare ACIU & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- DSM
- Stock Information
- Founded
- ACIU 2003
- DSM 1989
- Country
- ACIU Switzerland
- DSM United States
- Employees
- ACIU N/A
- DSM N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- DSM Investment Managers
- Sector
- ACIU Health Care
- DSM Finance
- Exchange
- ACIU Nasdaq
- DSM Nasdaq
- Market Cap
- ACIU 332.4M
- DSM 303.5M
- IPO Year
- ACIU 2016
- DSM N/A
- Fundamental
- Price
- ACIU $3.15
- DSM $6.12
- Analyst Decision
- ACIU Strong Buy
- DSM
- Analyst Count
- ACIU 2
- DSM 0
- Target Price
- ACIU $12.00
- DSM N/A
- AVG Volume (30 Days)
- ACIU 153.3K
- DSM 161.7K
- Earning Date
- ACIU 11-05-2024
- DSM 01-01-0001
- Dividend Yield
- ACIU N/A
- DSM 3.97%
- EPS Growth
- ACIU N/A
- DSM N/A
- EPS
- ACIU N/A
- DSM N/A
- Revenue
- ACIU $48,505,404.00
- DSM N/A
- Revenue This Year
- ACIU $85.33
- DSM N/A
- Revenue Next Year
- ACIU $80.69
- DSM N/A
- P/E Ratio
- ACIU N/A
- DSM N/A
- Revenue Growth
- ACIU 4097200.00
- DSM N/A
- 52 Week Low
- ACIU $2.25
- DSM $4.69
- 52 Week High
- ACIU $5.14
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- ACIU 45.68
- DSM 55.38
- Support Level
- ACIU $3.10
- DSM $6.09
- Resistance Level
- ACIU $3.25
- DSM $6.18
- Average True Range (ATR)
- ACIU 0.14
- DSM 0.05
- MACD
- ACIU -0.02
- DSM 0.02
- Stochastic Oscillator
- ACIU 13.16
- DSM 73.91
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.